Skip to main content

Advertisement

SpringerLink
Log in

Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases in childhood with a prevalence of 4 in 1,000 children. Anterior uveitis is a well-known threatening comorbid condition of JIA and affects around 10 % of the patients depending on JIA subtype. A large proportion of children with JIA develop uveitis in the first year of disease and 73 to 90 % after 4 years. Uveitis can progress into adulthood and usually occurs as ‘white uveitis’, while in the JIA related to the enthesitis subtype that is symptomatic. Current studies reinforced the previous observations that early age of JIA onset, oligoarticular subtype and ANA reactivity are the main risk factors for the development of uveitis. Factors associated to worse prognosis are as follows: findings of 1+ or more vitreous cells at presentation and initial visual acuity of 20/200 or worse. The Standardization of Uveitis Nomenclature (SUN) Group took the first step to define outcome measures for uveitis, but it was established for adults. The Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) proposed outcome measures for JIA-associated uveitis incorporating the SUN criteria in 2011. The current suggested management recommends to start early a steroid-sparing effective immunomodulatory systemic treatment. Methylprednisolone intravenous pulse therapy, rituximab, tocilizumab and abatacept are promising agents. Because JIA-associated uveitis is a potentially threatening comorbidity, it is important to recognize and treat it early to prevent any visual damage that could impair visual acuity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Photo 1
Fig. 1

Similar content being viewed by others

References

  1. Gowdie PJ, Tse SM (2012) Juvenile idiopathic arthritis. Pediatr Clin N Am 59(2):301–327

    Article  Google Scholar 

  2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392

    PubMed  Google Scholar 

  3. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019

    Article  CAS  Google Scholar 

  4. Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM (2013) Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology (Oxford) 52(11):1999–2003

    Article  Google Scholar 

  5. Hoeve M, Kalinina Ayuso V, Schalij-Delfos NE, Los LI, Rothova A, de Boer JH (2012) The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol 96(6):852–856

    Article  PubMed  Google Scholar 

  6. Reininga JK, Los LI, Wulffraat NM, Armbrust W (2008) The evaluation of uveitis in juvenile idiopathic arthritis (JIA) patients: are current ophthalmologic screening guidelines adequate? Clin Exp Rheumatol 26(2):367–372

    CAS  PubMed  Google Scholar 

  7. Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21(3):180–191

    Article  PubMed  Google Scholar 

  8. Angeles-Han ST, Pelajo CF, Vogler LB, Rouster-Stevens K, Kennedy C, Ponder L et al (2013) Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 40(12):2088–2096

    Article  PubMed Central  PubMed  Google Scholar 

  9. Cole TS, Frankovich J, Iyer S, Lependu P, Bauer-Mehren A, Shah NH (2013) Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research. Pediatr Rheumatol Online J 11(1):45

    Article  PubMed Central  PubMed  Google Scholar 

  10. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R et al (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 56(2):647–657

    Article  CAS  PubMed  Google Scholar 

  11. Anesi SD, Foster CS (2012) Importance of recognizing and preventing blindness from juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken) 64(5):653–657

    Article  Google Scholar 

  12. Artornsombudh P, Pistilli M, Foster CS, Pujari SS, Gangaputra SS, Jabs DA et al (2014) Factors predictive of remission of new-onset anterior uveitis. Ophthalmology 121(3):778–784

    Article  PubMed Central  PubMed  Google Scholar 

  13. Gregory AC 2nd, Kempen JH, Daniel E, Kacmaz RO, Foster CS, Jabs DA et al (2013) Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 120(1):186–192

    Article  PubMed Central  PubMed  Google Scholar 

  14. Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31(11):2290–2294

    PubMed  Google Scholar 

  15. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516

    Article  PubMed  Google Scholar 

  16. Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B et al (2012) Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken) 64(9):1365–1372

    Article  Google Scholar 

  17. Kalinina Ayuso V, de Boer JH, Byers HL, Coulton GR, Dekkers J, de Visser L et al (2013) Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci 54(5):3709–3720

    Article  PubMed  Google Scholar 

  18. Chasnyk V, Nekhai S, Hynes A, Ammosova T, Obukhov Y, Gaidar E et al (2013) Proteomic profile of the tears—can it help to diagnose juvenile idiopathic arthritis associated uveitis prior to the clinical sign of joint inflammation. Arthritis and Rheumatism. 65(10 (Supplement)):abstract #1891

  19. Tempest-Roe S, Joshi L, Dick AD, Taylor SR (2013) Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol 13(1):39

    Article  PubMed Central  PubMed  Google Scholar 

  20. Palejwala NV, Yeh S, Angeles-Han ST (2013) Current perspectives on ophthalmic manifestations of childhood rheumatic diseases. Curr Rheumatol Rep 15(7):341

    Article  PubMed Central  PubMed  Google Scholar 

  21. Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T et al (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32(5):1121–1133

    Article  CAS  PubMed  Google Scholar 

  22. Tappeiner C, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A (2008) Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 23:1192–1198

    Article  PubMed  Google Scholar 

  23. Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ (2013) Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford) 52(5):825–831

    Article  CAS  Google Scholar 

  24. Sen ES, Sharma S, Hinchcliffe A, Dick AD, Ramanan AV (2012) Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease—a case cohort interventional study. Rheumatology (Oxford) 51(12):2199–2203

    Article  CAS  Google Scholar 

  25. Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gomez J (2013) Adalimumab therapy for refractory childhood uveitis. J AAPOS 17(5):456–459

    Article  PubMed  Google Scholar 

  26. Magli A, Forte R, Navarro P, Russo G, Orlando F, Latanza L et al (2013) Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 251(6):1601–1606

    Article  CAS  PubMed  Google Scholar 

  27. Little JA, Sen ES, Strike H, Hinchcliffe A, Guly CM, Lee RW et al (2014) The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. J Rheumatol 41(1):136–139

    Article  CAS  PubMed  Google Scholar 

  28. Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F et al (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11(1):16

    Article  PubMed Central  PubMed  Google Scholar 

  29. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 63(4):612–618

    Article  CAS  Google Scholar 

  30. Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 40(1):74–79

    Article  CAS  PubMed  Google Scholar 

  31. Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B et al (2014) A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 15:14

    Article  PubMed Central  PubMed  Google Scholar 

  32. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50(8):1390–1394

    Article  CAS  Google Scholar 

  33. Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295

    Article  PubMed  Google Scholar 

  34. Mesquida M, Leszczynska A, Llorenc V, Adan A (2014) Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol 176(3):301–309

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Tsang AC, Roth J, Gottlieb C (2013) Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm 22(2):155–157

    Article  PubMed  Google Scholar 

  36. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62(6):821–825

    Article  CAS  Google Scholar 

  37. Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken) 63(2):307–308, author reply 8

    Article  Google Scholar 

  38. Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249(2):297–300

    Article  PubMed  Google Scholar 

  39. Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis—a case report. J Rheumatol 35(9):1897–1898

    PubMed  Google Scholar 

  40. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787

    Article  PubMed  Google Scholar 

  41. Wakefield D, McCluskey P, Penny R (1986) Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 104(6):847–851

    Article  CAS  PubMed  Google Scholar 

  42. Saboo US, Metzinger JL, Radwan A, Arcinue C, Parikh R, Mohamed A et al (2013) Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: a preliminary report. J AAPOS 17(5):460–464

    Article  PubMed  Google Scholar 

  43. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH (2010) Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 151(2):217–222

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

To Christianne Diniz for her careful and critical review of the paper.

Author information

Authors and Affiliations

  1. Hamburger Zentrum für Kinder- und Jugendrheumatologie am Klinikum Eilbek, Dehnhaide 120, 22081, Hamburg, Germany

    Ivan Foeldvari

Authors
  1. Ivan Foeldvari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan Foeldvari.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Foeldvari, I. Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment. Clinic Rev Allerg Immunol 49, 271–277 (2015). https://doi.org/10.1007/s12016-014-8436-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-014-8436-9

Keywords

Search

Navigation